212 related articles for article (PubMed ID: 15008715)
21. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
Di Lorenzo G; Perdonà S; Damiano R; Faiella A; Cantiello F; Pignata S; Ascierto P; Simeone E; De Sio M; Autorino R
Cancer; 2010 Apr; 116(8):1893-900. PubMed ID: 20162706
[TBL] [Abstract][Full Text] [Related]
22. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
23. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.
Witjes JA; Vriesema JL; van der Heijden AG; Peters GJ; Schalken JA
Eur Urol; 2003 Nov; 44(5):615-9. PubMed ID: 14572765
[TBL] [Abstract][Full Text] [Related]
25. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
Maffezzini M; Campodonico F; Canepa G; Capponi G; Fontana V
Eur Urol; 2007 Apr; 51(4):956-61. PubMed ID: 17027141
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
Kohjimoto Y; Iba A; Shintani Y; Uekado Y; Shinka T
Hinyokika Kiyo; 2005 Aug; 51(8):533-8. PubMed ID: 16164269
[TBL] [Abstract][Full Text] [Related]
27. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Cao M; Ma CK; Ma J; Chen HG; Xue W
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):385-7. PubMed ID: 21875472
[TBL] [Abstract][Full Text] [Related]
29. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.
Gunelli R; Bercovich E; Nanni O; Ballardini M; Frassineti GL; Giovannini N; Fiori M; Pasquini E; Ulivi P; Pappagallo GL; Silvestrini R; Zoli W
Br J Cancer; 2007 Dec; 97(11):1499-504. PubMed ID: 17987035
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
Campodonico F; Maffezzini M
Urology; 2005 Nov; 66(5):1141-2; author reply 1142. PubMed ID: 16286156
[No Abstract] [Full Text] [Related]
31. Actual experience and future development of gemcitabine in superficial bladder cancer.
Gontero P; Frea B
Ann Oncol; 2006 May; 17 Suppl 5():v123-8. PubMed ID: 16807439
[TBL] [Abstract][Full Text] [Related]
32. Microemulsions for intravesical delivery of gemcitabine.
Tsai YH; Hsieh YH; Huang YB; Chang JS; Huang CT; Wu PC
Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1461-5. PubMed ID: 21048337
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
Gårdmark T; Carringer M; Beckman E; Malmström PU;
Urology; 2005 Sep; 66(3):527-30. PubMed ID: 16140071
[TBL] [Abstract][Full Text] [Related]
34. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience.
Mohanty NK; Nayak RL; Vasudeva P; Arora RP
Urol Oncol; 2008; 26(6):616-9. PubMed ID: 18367121
[TBL] [Abstract][Full Text] [Related]
35. The effects of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin in superficial bladder cancer: a preliminary study.
Cho DY; Bae JH; Moon DG; Cheon J; Lee JG; Kim JJ; Yoon DK; Park HS
J Int Med Res; 2009; 37(6):1823-30. PubMed ID: 20146880
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
Sangar VK; McBain CA; Lyons J; Ramani VA; Logue JP; Wylie JP; Clarke NW; Cowan RA
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):420-5. PubMed ID: 15667962
[TBL] [Abstract][Full Text] [Related]
37. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs.
Cozzi PJ; Bajorin DF; Tong W; Nguyen H; Scott J; Heston WD; Dalbagni G
Clin Cancer Res; 1999 Sep; 5(9):2629-37. PubMed ID: 10499642
[TBL] [Abstract][Full Text] [Related]
38. Intravesical therapy for superficial cancer: need for more options.
Crawford ED
J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
[No Abstract] [Full Text] [Related]
39. Editorial comment.
Berglund RK
Urology; 2009 Nov; 74(5):1083; author reply 1084. PubMed ID: 19883829
[No Abstract] [Full Text] [Related]
40. Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine.
Kurtzhalts K; Gee ME; Feuz L; Krajewski KC
Am J Health Syst Pharm; 2016 Oct; 73(19):1508-11. PubMed ID: 27646812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
